The Ultimaster Biodegradable-Polymer Sirolimus-Eluting Stent: An Updated Review of Clinical Evidence

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2016 Sep 9

PMID 27608017

Citations 20

Authors

Alberto Chisari

Anna Maria Pistritto

Raffaele Piccolo

Alessio La Manna

Gian Battista Danzi

Affiliations

Soon will be listed here.

Abstract

The Ultimaster coronary stent system (Terumo Corporation, Tokyo, Japan) represents a new iteration in drug-eluting stent (DES) technology that has recently received the Conformité Européenne (CE) mark approval for clinical use. The Ultimaster is a thin-strut, cobalt chromium, biodegradable-polymer, sirolimus-eluting coronary stent. The high elasticity of the biodegradable-polymer (PDLLA-PCL) and the abluminal gradient coating technology are additional novel features of this coronary device. The Ultimaster DES has undergone extensive clinical evaluation in two studies: The CENTURY I and II trials. Results from these two landmark studies suggested an excellent efficacy and safety profile of the Ultimaster DES across several lesion and patient subsets, with similar clinical outcomes to contemporary, new-generation DES. The aim of this review is to summarize the rationale behind this novel DES technology and to provide an update of available evidence about the clinical performance of the Ultimaster DES.

Citing Articles

Impact of the number of modifiable risk factors on clinical outcomes after percutaneous coronary intervention: An analysis from the e-Ultimaster registry.

Kobo O, Levi Y, Abu-Fanne R, von Birgelen C, Guedes A, Aminian A Int J Cardiol Heart Vasc. 2024; 51:101370.

PMID: 38628296 PMC: 11018637. DOI: 10.1016/j.ijcha.2024.101370.

Cells in Atherosclerosis: Focus on Cellular Senescence from Basic Science to Clinical Practice.

Molnar A, Pasztor D, Tarcza Z, Merkely B Int J Mol Sci. 2023; 24(24).

PMID: 38138958 PMC: 10743093. DOI: 10.3390/ijms242417129.

Is There an Advantage of Ultrathin-Strut Drug-Eluting Stents over Second- and Third-Generation Drug-Eluting Stents?.

Gherasie F, Valentin C, Busnatu S J Pers Med. 2023; 13(5).

PMID: 37240923 PMC: 10219486. DOI: 10.3390/jpm13050753.

Drug-Eluting Stents: Technical and Clinical Progress.

Kozlik M, Harpula J, Chuchra P, Nowak M, Wojakowski W, Gasior P Biomimetics (Basel). 2023; 8(1).

PMID: 36810403 PMC: 9944483. DOI: 10.3390/biomimetics8010072.

The path to a hemocompatible cardiovascular implant: Advances and challenges of current endothelialization strategies.

Exarchos V, Zacharova E, Neuber S, Giampietro C, Motta S, Hinkov H Front Cardiovasc Med. 2022; 9:971028.

PMID: 36186971 PMC: 9515323. DOI: 10.3389/fcvm.2022.971028.

References

Wenaweser P, Daemen J, Zwahlen M, van Domburg R, Juni P, Vaina S . Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. J Am Coll Cardiol. 2008; 52(14):1134-40. DOI: 10.1016/j.jacc.2008.07.006. View

Camenzind E, Steg P, Wijns W . Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation. 2007; 115(11):1440-55. DOI: 10.1161/CIRCULATIONAHA.106.666800. View

Lesiak M, Araszkiewicz A, Grajek S, Colombo A, Lalmand J, Carstensen S . Long Coronary Lesions Treated With Thin Strut Bioresorbable Polymer Drug Eluting Stent: Experience From Multicentre Randomized CENTURY II Study. J Interv Cardiol. 2016; 29(1):47-56. DOI: 10.1111/joic.12262. View

Piccolo R, Cassese S, Galasso G, de Rosa R, DAnna C, Piscione F . Long-term safety and efficacy of drug-eluting stents in patients with acute myocardial infarction: a meta-analysis of randomized trials. Atherosclerosis. 2011; 217(1):149-57. DOI: 10.1016/j.atherosclerosis.2011.03.007. View

Piccolo R, Stefanini G, Franzone A, Spitzer E, Blochlinger S, Heg D . Safety and efficacy of resolute zotarolimus-eluting stents compared with everolimus-eluting stents: a meta-analysis. Circ Cardiovasc Interv. 2015; 8(4). DOI: 10.1161/CIRCINTERVENTIONS.114.002223. View

Cassese S, Piccolo R, Galasso G, de Rosa R, Piscione F . Twelve-month clinical outcomes of everolimus-eluting stent as compared to paclitaxel- and sirolimus-eluting stent in patients undergoing percutaneous coronary interventions. A meta-analysis of randomized clinical trials. Int J Cardiol. 2011; 150(1):84-9. DOI: 10.1016/j.ijcard.2011.01.015. View

Cook S, Ladich E, Nakazawa G, Eshtehardi P, Neidhart M, Vogel R . Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. Circulation. 2009; 120(5):391-9. DOI: 10.1161/CIRCULATIONAHA.109.854398. View

Piccolo R, Nicolino A, Danzi G . The Nobori biolimus-eluting stent: update of available evidence. Expert Rev Med Devices. 2014; 11(3):275-82. DOI: 10.1586/17434440.2014.894458. View

Finn A, Nakazawa G, Joner M, Kolodgie F, Mont E, Gold H . Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol. 2007; 27(7):1500-10. DOI: 10.1161/ATVBAHA.107.144220. View

10.

Kuramitsu S, Kazuno Y, Sonoda S, Domei T, Jinnouchi H, Yamaji K . Vascular response to bioresorbable polymer sirolimus-eluting stent vs. permanent polymer everolimus-eluting stent at 9-month follow-up: an optical coherence tomography sub-study from the CENTURY II trial. Eur Heart J Cardiovasc Imaging. 2015; 17(1):34-40. PMC: 4684161. DOI: 10.1093/ehjci/jev203. View

11.

Jeremias A, Kirtane A . Balancing efficacy and safety of drug-eluting stents in patients undergoing percutaneous coronary intervention. Ann Intern Med. 2007; 148(3):234-8. DOI: 10.7326/0003-4819-148-3-200802050-00199. View

12.

Lagerqvist B, James S, Stenestrand U, Lindback J, Nilsson T, Wallentin L . Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med. 2007; 356(10):1009-19. DOI: 10.1056/NEJMoa067722. View

13.

Piccolo R, Cassese S, Galasso G, Niglio T, de Rosa R, De Biase C . Long-term clinical outcomes following sirolimus-eluting stent implantation in patients with acute myocardial infarction. A meta-analysis of randomized trials. Clin Res Cardiol. 2012; 101(11):885-93. DOI: 10.1007/s00392-012-0472-y. View

14.

Danzi G, Piccolo R, Galasso G, Piscione F . Nobori biolimus-eluting stent vs. permanent polymer drug-eluting stents in patients undergoing percutaneous coronary intervention. Circ J. 2014; 78(8):1858-66. DOI: 10.1253/circj.cj-13-1558. View

15.

Barbato E, Salinger-Martinovic S, Sagic D, Beleslin B, Vrolix M, Neskovic A . A first-in-man clinical evaluation of Ultimaster, a new drug-eluting coronary stent system: CENTURY study. EuroIntervention. 2014; 11(5):541-8. DOI: 10.4244/EIJY14M08_06. View

16.

Wohrle J, Markovic S, Rottbauer W, Muramatsu T, Kadota K, Vazquez-Gonzalez N . Bioresorbable polymer sirolimus-eluting coronary stent compared with permanent polymer everolimus-eluting coronary stent implantation for treatment of small vessel coronary artery disease: CENTURY II trial. EuroIntervention. 2016; 12(2):e167-74. DOI: 10.4244/EIJV12I2A30. View

17.

Saito S, Valdes-Chavarri M, Richardt G, Moreno R, Iniguez Romo A, Barbato E . A randomized, prospective, intercontinental evaluation of a bioresorbable polymer sirolimus-eluting coronary stent system: the CENTURY II (Clinical Evaluation of New Terumo Drug-Eluting Coronary Stent System in the Treatment of Patients with.... Eur Heart J. 2014; 35(30):2021-31. PMC: 4200026. DOI: 10.1093/eurheartj/ehu210. View

18.

Stefanini G, Byrne R, Serruys P, de Waha A, Meier B, Massberg S . Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS.... Eur Heart J. 2012; 33(10):1214-22. DOI: 10.1093/eurheartj/ehs086. View

19.

Joner M, Finn A, Farb A, Mont E, Kolodgie F, Ladich E . Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006; 48(1):193-202. DOI: 10.1016/j.jacc.2006.03.042. View

20.

Stettler C, Wandel S, Allemann S, Kastrati A, Morice M, Schomig A . Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet. 2007; 370(9591):937-48. DOI: 10.1016/S0140-6736(07)61444-5. View